Advertisement
BDX vs TMO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BDX and TMO operate in the healthcare sector with BDX focused on medical devices and TMO on life sciences tools and services, leading to differing exposure to end-market demand.
- Recent market activity shows TMO delivering stronger revenue growth in its latest quarter compared to BDX’s steadier but more modest performance.
- Both stocks have posted positive year-to-date returns, though TMO’s larger market capitalization and recent guidance raise have influenced relative momentum.
- Risk factors include regulatory and reimbursement pressures for BDX alongside broader biotech spending trends affecting TMO.
- Sector sentiment remains constructive for both amid ongoing healthcare innovation, with earnings catalysts playing a key role in short-term price behavior.
- Market positioning highlights TMO’s scale advantage versus BDX’s specialized device portfolio in current conditions.
Introduction
Investors and traders frequently compare BDX and TMO due to their prominent roles in the healthcare equipment and life sciences industries. This analysis examines their business models, recent stock behavior, and relative performance to assist those evaluating sector exposure or seeking diversification within medical technology. The comparison draws on observable market data and developments from recent weeks, providing a neutral framework relevant to institutional portfolio managers, active traders monitoring earnings cycles, and individual investors assessing long-term holdings in defensive growth areas.
BDX Overview and Recent Performance
Becton, Dickinson and Company develops, manufactures, and sells medical devices, instrument systems, and reagents primarily for healthcare institutions worldwide. In recent market activity, the stock has traded in a range reflecting measured gains, with year-to-date returns near 10% as of late July 2026. Performance has been supported by consistent dividend declarations and operational updates, while upcoming third-quarter fiscal 2026 results scheduled for early August have contributed to cautious sentiment. Broader influences include stable demand for core product lines offset by considerations around cash flow and market conditions, resulting in relatively contained volatility compared to more growth-oriented peers.
TMO Overview and Recent Performance
Thermo Fisher Scientific provides analytical instruments, reagents, consumables, software, and services to life sciences, healthcare, and applied markets globally. Recent performance has featured a notable response to second-quarter 2026 results released in late July, which showed revenue growth of 10% and an organic increase of 5%, prompting an upward revision to full-year guidance. The stock registered gains following the report amid improved customer demand across segments. With a substantially larger market capitalization, TMO’s price behavior in recent weeks has reflected positive earnings momentum while remaining subject to broader industry dynamics such as bioproduction trends.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI trading bots designed for copy trading across stocks, ETFs, and crypto. The platform features hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest and most suitable for prevailing market conditions are featured in the Trending section. Current highlights include 25 best AI Trending Bots selected from a total of 351 available robots. These bots encompass varied trading styles, strategies, timeframes, performance metrics, and ticker sets, spanning technical and fundamental approaches as well as different volatility environments. The page allows users to explore options by timeframe, asset class, and risk parameters for informed selection.
Head-to-Head Comparison
BDX centers on medical devices and diagnostics with revenue tied to hospital and laboratory spending, whereas TMO emphasizes life sciences instrumentation and bioproduction with broader exposure to research and pharmaceutical customers. Recent momentum favors TMO following its earnings beat and guidance increase, contrasting with BDX’s more stable trajectory ahead of its own quarterly report. Risk considerations differ: BDX faces device-specific regulatory and reimbursement variables, while TMO contends with biotech funding cycles and supply-chain factors. Sector exposure overlaps in healthcare but diverges in end-market sensitivity, with TMO’s larger scale providing greater liquidity and TMO’s recent catalysts offering sharper sentiment shifts than BDX’s steadier positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency following earnings and relative positioning in recent market activity, Tickeron’s AI would currently assign a probabilistic edge to TMO over BDX. The stronger revenue growth and guidance revision provide clearer near-term catalysts, though both stocks exhibit defensive characteristics suited to varying market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Buy and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 2 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 2 bullish TA indicator(s).
- BDX’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 2 bullish, 5 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +3.70% price change this week, while TMO (@Medical Specialties) price change was -0.96% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.26%. For the same industry, the average monthly price growth was +8.63%, and the average quarterly price growth was +6.97%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.84%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +23.29%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.26% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-0.84% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BDX | TMO | BDX / TMO | |
| Capitalization | 50B | 218B | 23% |
| EBITDA | 4.97B | 12B | 41% |
| Gain YTD | 21.791 | 1.728 | 1,261% |
| P/E Ratio | 31.73 | 31.66 | 100% |
| Revenue | 22.2B | 46.3B | 48% |
| Total Cash | N/A | 4.06B | - |
| Total Debt | 17.3B | 42.5B | 41% |
BDX | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 89 | 82 | |
SMR RATING 1..100 | 86 | 61 | |
PRICE GROWTH RATING 1..100 | 14 | 12 | |
P/E GROWTH RATING 1..100 | 62 | 35 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (7) in the Medical Specialties industry is in the same range as TMO (12). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as BDX (89). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
TMO's SMR Rating (61) in the Medical Specialties industry is in the same range as BDX (86). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
TMO's Price Growth Rating (12) in the Medical Specialties industry is in the same range as BDX (14). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
TMO's P/E Growth Rating (35) in the Medical Specialties industry is in the same range as BDX (62). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
| BDX | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 56% |
| Stochastic ODDS (%) | 1 day ago 46% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 50% | N/A |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 61% |
| Advances ODDS (%) | 4 days ago 44% | 5 days ago 62% |
| Declines ODDS (%) | 24 days ago 43% | 1 day ago 63% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 54% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.79% | ||
| COO - BDX | 54% Loosely correlated | -0.56% | ||
| BAX - BDX | 51% Loosely correlated | -1.18% | ||
| TMO - BDX | 50% Loosely correlated | -1.28% | ||
| CNMD - BDX | 48% Loosely correlated | +1.18% | ||
| SOLV - BDX | 47% Loosely correlated | +2.46% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.